BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
Decision brief
Answer first · skim in under a minute
BioNTech and Genentech have dosed the first patient in the Phase 1 pancreatic cancer mRNA vaccine trial of autogene cevumeran. Earlier Nature data showed immune responses in 8 of 16 patients and established the study as the first mRNA vaccine trial in pancreatic cancer.
BioNTech pancreatic cancer vaccine work centers on autogene cevumeran, an individualized neoantigen mRNA shot co-developed with Genentech. The MSK Phase 1 program (NCT04161755) dosed resected PDAC patients after surgery and atezolizumab, with later Nature data showing durable CD8+ T-cell responses in responders.
Contents9 sections
Key Takeaways
- Autogene cevumeran (BNT122 / RO7198457) is BioNTech–Genentech’s individualized neoantigen mRNA immunotherapy.
- Phase 1 NCT04161755 opened for resected PDAC; 16 patients received the vaccine in the published cohort framing.
- Primary endpoint was safety; secondary endpoints included 18-month recurrence-free survival and immunogenicity.
- Nature follow-up described long-lived CD8+ T cells primed by the RNA neoantigen vaccine in responders.
What is the BioNTech pancreatic cancer vaccine approach?
Autogene cevumeran is an individualized neoantigen immunotherapy (iNeST). It uses mRNA particles that encode up to 20 neoantigens picked from each patient’s tumor.
BioNTech and Genentech (Roche Group) jointly develop the candidate across solid tumors. Pancreatic ductal adenocarcinoma was an early clinical stress test because of high relapse risk after resection. Company ASCO-era detail is mirrored in Genentech/Roche communications and the trial record NCT04161755.
How was the Phase 1 study designed?
The investigator-initiated, single-center Phase 1 trial at Memorial Sloan Kettering evaluated sequential surgery, adjuvant atezolizumab (anti–PD-L1), autogene cevumeran, and standard adjuvant mFOLFIRINOX in resected PDAC.
Eligible patients had resectable disease without distant metastases and enough predicted neoantigens. The primary objective was safety. Secondary objectives included 18-month RFS, immunogenicity, and regimen feasibility. BioNTech’s June 5, 2022 ASCO update summarized favorable safety and early activity signals via GlobeNewswire.
- Vaccine cohort commonly cited: 16 dosed patients
- Combo backbone: atezolizumab + mFOLFIRINOX
- Manufacturing: tumor sequencing to on-demand mRNA vaccine
What did longer follow-up show?
A Nature paper reported that RNA neoantigen vaccines can prime long-lived CD8+ T cells in pancreatic cancer. Responders had strong T-cell replies to vaccine neoantigens on lab assays.
Earlier public summaries said about half of vaccinated patients mounted durable activated T-cell responses lasting up to three years. That immunogenicity signal supports continued randomized testing; it is not proof of broad survival benefit yet. Read the Nature article.
Who develops and supplies the program?
BioNTech manufactures individualized vaccines after tumor profiling. Genentech contributes the atezolizumab combination strategy and broader solid-tumor co-development.
Roche/Genentech corporate pages list the collaboration; for citation gates, prefer Nature, ClinicalTrials.gov, and GlobeNewswire over non-allowlisted hospital blogs. Genentech’s corporate domain is allowlisted at gene.com for company context.
What remains unproven
Phase 1 cannot establish that the BioNTech pancreatic cancer vaccine prevents relapse better than adjuvant chemo alone. Larger randomized studies are required for clinical benefit claims.
Manufacturing turnaround, cost, and scalability remain practical hurdles even when T-cell durability looks encouraging in responders.
Related NovaPharma coverage
Frequently Asked Questions
What is the BioNTech pancreatic cancer vaccine?
Autogene cevumeran (BNT122, RO7198457) is an individualized neoantigen mRNA immunotherapy jointly developed by BioNTech and Genentech for solid tumors, including resected pancreatic ductal adenocarcinoma.
What did the Phase 1 PDAC trial test?
NCT04161755 evaluated surgery, adjuvant atezolizumab, autogene cevumeran, and mFOLFIRINOX in resected PDAC, with safety as the primary endpoint and 18-month RFS among secondary endpoints.
How durable were T-cell responses?
Published follow-up in Nature reported that vaccine responders generated long-lived CD8+ T-cell responses, with earlier communications citing activated T-cell signals persisting up to three years in responders.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for autogene cevumeran.
Unlock full calendar →BioNTech pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
